This healthcare business was spun-off to raise funds for its parent. It now faces pressure from high interest expense and modest growth prospects.
However, competent new management has identified several areas for improvement, hinting at a compelling turnaround within the business.
At 11 times adjusted earnings much of the downside is priced in. Higher valuation multiples in line with peers, can lead the stock to double over the next few years.
Keep reading with a 7-day free trial
Subscribe to Overlooked Alpha to keep reading this post and get 7 days of free access to the full post archives.